Abstract:Objective To investigate the application effects of solifenacin combined with tamsulosin in mild and moderate benign prostatic hyperplasia with overactive bladder.Methods A total of 160 patients with mild and moderate benign prostatic hyperplasia and overactive bladder were chosen as experimental subjects,mild patients were divided into research group one and control group one,moderate patients were divided into re-search group two and control group two,each group were 40 cases,patients in research group were treated with solifenacin(5 mg each time,once per day)combined with tamsulosin(0.2 mg each time,once per day), patients in control group were treated with tamsulosin(0.2 mg each time,once per day),after 12 weeks'treat-ment,residual urine,Qmax,Voiding symptom score(VSS),Urine storage period symptom score(USPSS), Overactive bladder symptom score(OABSS),International Prostate Symptom Score(IPSS)and adverse reac-tions were compared.Results Before treatment,IPSS,USPSS,OABSS,residual urine and Qmax between re-search group one and control group one had no significant differences(t=0.333,0.448,0.269,0.081,0.384, P>0.05).After treatment,IPSS,USPSS,OABSS of research group one were lower than those in the control group one,Qmax was higher than that in the control group one,the differences were statistically different(t=8.692,8.095,9.264,6.065,P<0.05).Residual urine between two groups had no significant difference(t=0.081,0.456,P> 0.05).Before treatment,IPSS,VSS,OABSS,residual urine and Qmax between research group two and control group two had no significant difference(t=1.253,0.139,0.092,0.006,0.619,P>0. 05).After treatment,IPSS,VSS,residual urine and Qmax between the two groups had no significant differ-ences(t=0.096,1.678,0.478,0.456,P>0.05).OABSS of research group two was lower than that in the control group,the difference was statistically different(t=4.222,P<0.05).In mild and moderate patients, adverse reaction rate between research group one and control group one(12.50% vs.7.50%),research group two and control group two(10.00% vs 7.50%)had no significant differences(χ2=0.556,0.157,P>0.05). Conclusion Solifenacin combined with tamsulosin could effectively improve the clinical symptom of mild and moderate benign prostatic hyperplasia with overactive bladder,and with good safety,worthy of clinical promo-tion.

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study

Efficacy And Safety Of Combinations Of Mirabegron And Solifenacin In Patients With Overactive Bladder: A Systematic Review And Meta-Analysis

Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study

Clinical Study of Combination Therapy of Tamsulosin and Solifenacin for Benign Prostatic Hyperplasia with Overactive Bladder

Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials

Tamsulosin Combined with Solifenacin Versus Tamsulosin Monotherapy for Male Lower Urinary Tract Symptoms: a Meta-Analysis

Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial

A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms

Comparison of Mirabegron Plus Tamsulosin and Tamsulosin Monotherapy for the Treatment of Ureteral Stent-Related Symptoms: A Prospective Randomized Study

Application effects of solifenacin combined with tamsulosin in the mild and moderate benign prostatic hyperplasia with overactive bladder

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?

Efficacy of the combination of transcutaneous tibial nerve stimulation and mirabegron in women with overactive bladder in a prospective randomized controlled trial

Biofeedback-Assisted pelvic floor muscle training combined with a short-duration drug regimen is safe and effective in women with overactive bladder: A randomized controlled trial

Efficacy and Safety of Solifenacin Plus Tamsulosin Oral Controlled Absorption System in Men with Lower Urinary Tract Symptoms: a Meta-Analysis

Effect observation of Solifenacin in treating overactive bladder

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

[Safety of Solifenacin and Tolterodine in the Treatment of Overactive Bladder: a Meta-Analysis].

Overactive Bladder Symptom Score to Evaluate Efficacy of Solifenacin for the Treatment of Overactive Bladder Symptoms

[A Combination of Solifenacin Succinate and Naftopidil in the Treatment of Female Overactive Bladder].

Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-Related Symptoms—outcomes from a Network Meta-Analysis